Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03761017 · ClinicalTrials.gov registry record · Phase 1
MGD019 DART® Protein in Unresectable/Metastatic Cancer
A Phase 1 study, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 162
- Enrollment target
NCT03761017 is a Phase 1 study that has completed, run by MacroGenics. The registered enrollment target is 162 participants.
The verdict
NCT03761017, a Phase 1 study, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 162 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD) of MGD019. Dose escalation will occur in a 3+3+3 design in patients with advanced solid tumors of any histology. Once the MTD/MAD is determined, a Cohort Expansion Phase will be enrolled to further characterize safety and initial anti-tumor activity in patients with specific tumor types anticipated to be sensitive to dual checkpoint blockade.
Interventions
- BIOLOGICAL Lorigerlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2018-12-12 |
| Est. Completion | 2025-01-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03761017
The ClinicalTrials.gov registry entry for NCT03761017 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lorigerlimab is the first listed.
NCT03761017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03761017 about?
NCT03761017 is a clinical study titled "MGD019 DART® Protein in Unresectable/Metastatic Cancer". The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics (PK) pharmacodynamics and preliminary antitumor activity of lorigerlimab. This Phase 1, open-label study will characterize safety, dose-limiting toxicities (DLTs), and maximum tolerated/administered dose (MTD/MAD...
What is the current status of trial NCT03761017?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 162 participants. The study started on 2018-12-12. Estimated completion is 2025-01-27.
What interventions are being tested in trial NCT03761017?
The interventions under investigation include: Lorigerlimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03761017?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.